[https://www.nature.com/articles/s41588-025-02380-2\\\\]
In the article above, TGF-β is implicated in building a “dual immune barrier” in solid tumours by impairing T-cell recruitment and directing immunosuppressive macrophages.
By targeting Clever-1, clinical evidence suggests that Bexmarilimab reprograms immunosuppressive macrophages and reduces TGF-β signalling, removing barriers to T-cell activity.
In MDS, this translates into enhanced hematopoiesis, with increases in erythroid, leukocyte, and platelet progenitor cells, highlighting Bexmarilimab’s unique ability to modulate both innate and adaptive immunity, and restore normal blood formation.
In solid tumours, the same mechanism mirrors pathways implicated in resistance to immune checkpoint inhibitors, namely TGF-β signalling, suggesting that Bexmarilimab could synergise with ICIs to overcome immune suppression / treatment resistance by remodelling the extra-cellular-matrix. This reinforces the drug’s potential as a synergistic combination partner across multiple cancer / therapeutic types, building on mono-therapy data from Matins.
The case for Faron having a truly upstream, pan-cancer platform-in-a-drug continues to grow as clinical data emerges, consistently presented at major healthcare conferences, underscoring its potential as a safe, versatile, and potentially transformative immuno-oncology therapeutic.